Trevi Therapeutics Inc. announced that it expects its cash resources to fund operations into 2029. This updated guidance was disclosed in an SEC filing.
This represents a significant extension of the company's financial runway, previously guided into the second half of 2026. The extended cash runway provides substantial financial stability.
The prolonged funding period supports the advancement of Haduvio through late-stage development and key clinical milestones, as well as enabling pre-commercial planning activities without immediate financing pressure.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.